Metastatic prostate cancer (PCa) remains a leading cause of death in men worldwide (1). Although effective treatments exist, therapy resistance in PCa is common. Dr. Rodriguez-Bravo and her research team recently uncovered high chromosomal instability (CIN) and increased mitotic...
Head and neck cancer (HNC), describing cancers of the oral cavity, throat, nose, and sinuses, is the sixth most common cancer worldwide accounting for 300,000 cancer deaths each year. Epidemiological data has shown disparities between HNC screening, detection, treatment,...
Treatment options for brain cancers, including aggressive glioblastoma, are limited despite the availability of several chemotherapeutic drugs due to the inability of these drugs to cross the blood-brain barrier (BBB). AACR-Novocure grantee Dr. Carsten Hagemann and his team showed that the use of low-intensity alternating electric fields known as Tumor Treating Fields (TTFields), an FDA-approved treatment modality, can facilitate drugs crossing the BBB. Using multiple models, they elucidated the mechanisms driving this action.
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and young adults. Dr. Amit Sabnis, recipient of the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research, and his research team demonstrated the therapeutic potential of bi-steric mTORC1 inhibitors in FOXO1 fusion positive RMS.
One of the 2021 AACR-Novocure Tumor Treating Fields Research Grant recipients, Maurizio D’Incalci, MD, seeks to elucidate the molecular mechanisms behind the combinatorial efficacy of TTFields /chemotherapy.
Chemotherapy-induced cognitive impairment (CICI), also known as chemobrain, can affect up to 75% of patients during treatment. Recipient of the 2019 The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Alfredo Oliveros, PhD, and his colleagues showed that inhibiting adenosine A2A receptor signaling can prevent cisplatin-induced cognitive impairment.
In the midst of the excitement surrounding CAR T therapies, much needs to be done to optimize CAR T cell efficacy. 2017 AACR Next Gen Grant Recipient Sidi Chen, PhD leveraged in vivo genome engineering methods and identified a new target to do just that.
Cachexia is a muscle-wasting syndrome that is commonly found in pancreatic and other cancer patients. A group led by 2017 Pancreatic Cancer Action Network-AACR Career Development Award recipient Jason D. Doles, PhD, identified Perp as a novel tumor promoter and mediator of cancer-associated muscle wasting.
2019 AACR-Amgen Fellow, Julia Frede, PhD, reported in Nature Cell Biology, how treatment can induce the expression of a distinct set of actionable immunotherapy targets in multiple myeloma, such as CXCR4, which can be exploited to keep treatment resistance at bay.
2020 AACR-AstraZeneca Immuno-Oncology Fellow, Maria Casanova-Acebes, PhD, now current head of the Cancer Immunity Group at the Spanish National Cancer Research Centre (CNIO), reported in Nature their findings on how tissue-resident macrophages may influence lung cancer development.